Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 372

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 372
---
 the purposes of
assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating
units). The Group at 31 December 2023 had only one cash generating unit (2022: one, 2021: one). Non-financial assets other than goodwill
that suffered impairment are reviewed for possible reversal of impairment at each reporting date.

Patents and trademarks

The costs incurred in
establishing patents and trademarks are either expensed in accordance with the corresponding treatment of the development expenditure
for the product to which they relate or capitalised if the development expenditure to which they relate has reached the point of capitalisation
as an intangible asset.

| F-34 |

| 1 | Accounting policies (continued) |

Foreign currency

Transactions entered
into by Group entities in a currency other than the currency of the primary economic environment, in which they operate, are recorded
at the rates ruling when the transactions occur. Foreign currency monetary assets and liabilities are translated at the rates ruling at
the reporting date. Exchange differences arising on the retranslation of unsettled monetary assets and liabilities are recognised immediately
in profit or loss.

The presentational currency
of the Group is Pounds Sterling. Foreign subsidiaries use the local currencies of the country where they operate. On consolidation, the
results of overseas operations are translated into Pounds Sterling at rates approximating to those ruling when the transactions took place.
All assets and liabilities of overseas operations, including goodwill arising on the acquisition of those operations, are translated at
the rate ruling at the reporting date. Exchange differences arising on translating the opening net assets at opening rate and the results
of overseas operations at actual rate are recognised in other comprehensive income and accumulated in the foreign exchange reserve.

Exchange differences
recognised in the profit or loss of Group entities on the translation of long-term monetary items forming part of the Group’s net
investment in the overseas operation concerned are reclassified to other comprehensive income and accumulated in the foreign exchange
reserve on consolidation.

On disposal of a foreign
operation, the cumulative exchange differences recognised in the foreign exchange reserve relating to that operation up to the date of
disposal are transferred to the consolidated statement of comprehensive income as part of the gain or loss on disposal.

Financial assets and liabilities

Assets at amortised
cost

The Group does not have
any financial assets which it would classify as fair value through profit or loss. Therefore, all financial assets are classed as assets
at amortised cost as defined below